Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BMS and Merck Metformin Tablets in Healthy Subjects
NCT02183571Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2009
- Primary completion
- Apr 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity and Maximum plasma concentration. Started Feb 2009; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183571.